国家神经系统疾病临床医学研究中心数据管理与共享系统
Data Management And Sharing System of China National Clinical Research Center for Neurological Diseases
Time Course for Benefit and Risk With Ticagrelor and Aspirin in Individuals With Acute Ischemic Stroke or Transient Ischemic Attack Who Carry CYP2C19 Loss-of-Function Alleles: A Secondary Analysis of the CHANCE-2 Randomized Clinical Trial
第一作者：Yuesong Pan
通讯作者：Yongjun Wang
基本信息
- 负责人：Yuesong Pan
- 数据来源： CHANCE-2
- 论文编号：CHANCE-220220136
- 发表时间：2022-08-01
2022-08-01
已发表文章
主要研究背景及目的
Dual antiplatelet therapy (DAPT) with ticagrelor and aspirin has been found to be effective for secondary prevention after minor ischemic stroke or transient ischemic attack (TIA) in individuals who carry CYP2C19 loss-of-function (LOF) alleles; however, uncertainties remain about the time course of benefit and risk with ticagrelor and aspirin in these patients.
方法
The Ticagrelor or Clopidogrel With Aspirin in High-risk Patients With Acute Nondisabling Cerebrovascular Events II (CHANCE-2) randomized clinical trial enrolled patients 40 years and older from 202 hospitals in China with acute minor stroke or TIA who carried CYP2C19 LOF alleles between September 23, 2019, and March 22, 2021, and were followed up for 90 days. All 6412 patients enrolled in the CHANCE-2 trial were included in this secondary analysis. Data were analyzed in October 2021. Ticagrelor (180mg on day 1 followed by 90mg twice daily on days 2-90) or clopidogrel (300mg on day 1 followed by 75mg daily on days 2-90). All patients received aspirin (75-300mg on day 1 followed by 75mg daily for 21 days).
结论
Among patients with minor stroke or TIA who carried CYP2C19 LOF alleles, benefit with ticagrelor and aspirin was present predominately in the first week, with additional small benefit accruing in the next 2 weeks.
主要结果
A total of 6412 patients were included (3205 in the ticagrelor and aspirin group and 3207 in the clopidogrel and aspirin group). The median (IQR) age was 65 (57-71) years, and 4242 patients (66%) were men. The reduction of major ischemic events with ticagrelor and aspirin predominately occurred in the first week (absolute risk reduction, 1.34%; 95%CI, 0.29 to 2.39) and attenuated but remained in the next 3 weeks (absolute risk reduction in the second week, 0.11%; 95%CI, −0.24 to 0.45; absolute risk reduction in the third week, 0.14%; 95%CI, −0.11 to 0.38; absolute risk reduction in the fourth week, 0.04%; 95%CI, −0.18 to 0.25). The risk of moderate to severe bleeding was consistently low in the ticagrelor and aspirin group. The absolute increase in any bleeding seen in the first week (0.87%; 95%CI, 0.25 to 1.50) remained in the next 3 weeks (absolute increase in the second week, 1.21%; 95%CI, 0.75 to 1.68; absolute increase in the third week, 0.33%; 95%CI, −0.05 to 0.72; absolute increase in the fourth week, 0.23%; 95%CI, −0.03 to 0.49).